Anesthetic Management in Patients Undergoing Epicardial Ablation

Anesthetic Management in Patients Undergoing Epicardial Ablation for the Treatment of Ventricular Tachycardia; Retrospective Study

The study is a retrospective study and is descriptive in nature. In this study, the investigators aimed to emphasize the importance of anesthesia management by cardiac risk assessment of patients undergoing epicardial ablation under general anesthesia and analysis of complications that developed during the procedure.

Study Overview

• Status: Completed
• Conditions: Ventricular Tachycardia
• Intervention / Treatment: Procedure: percutaneous epicardial ablation

Detailed Description

The study is retrospective observational and data were collected by examining the files of all epicardial ablation patients received in the angiography unit starting from 30.10.2020 until 30.10.2022 after ethics committee approval is obtained. Baseline characteristic features of the patients Sex, Age, (years, BMI (kg/m2) Hypertension, Coronary artery disease, COPD (Chronic obstructive pulmonary disease), CKD (Chronic kidney disease) Electrical storm, and ventricular tachycardia etiology, Ischemic cardiomyopathy, Dilated cardiomyopathy, the presence of ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy), Hypertrophic cardiomyopathy will be recorded. NHYA classification will be examined in two groups as NHYA I or II and NHYA III or IV, also estimated glomerular filtration rate, left ventricular ejection fraction, PAAINESD (acute hemodynamic decompensation risk assessment score), iVT score (Risk of VT recurrence) Score information will be recorded. Ventricular tachycardia focus locations, dopamine, dobutamine, norepinephrine infusion requirement during the procedure, arrest development during the procedure, fluoroscopy time and ablation times will be recorded. In the follow-up of the patients after the procedure Causes of death, decompensated heart failure, transient ischemic attack, development of acute renal failure, and recurrence of ventricular tachycardia will be recorded. PAAINESD score (acute hemodynamic decompensation risk assessment score) will be recorded. The PAAINESD Score, developed to estimate the risk of periprocedural hemodynamic decompensation, has values ranging from 0 to 35 points (or 0 to 31 [PAINESD] when the modifiable intraprocedural variable "general anesthesia" is excluded). duration of the procedure, the need for inotropes during the procedure, whether the patient needed mechanical ventilation after the procedure, and the success rates after the procedure will be recorded.

PAINESD Pulmonary disease (chronic obstructive pulmonary disease) 5 Age >60 years 3 Anaesthesia (general) 4 Ischaemic cardiomyopathy 6 NYHA class III or IV 6 Ejection fraction <25 % 3 Storm (VT). 5 Diabetes 3 Data will be analyzed in three separate categories, the characteristics of the patients before the procedure, during the procedure and after the procedure. Descriptive tables and percentages of parameters will be created by statistical analysis.

• Study Type: Observational
• Enrollment (Actual): 22

Contacts and Locations

Study Locations

• Turkey
  • Odunpazarı
    • Eski̇şehi̇r, Odunpazarı, Turkey, 26040
      • University of Eskisehir Osmangazi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Since it is a retrospective study, patients who underwent epicardial ablation within the specified date range will be included. Although the estimated number of cases cannot be predicted, it is a rare and specialized procedure. No group has been determined, the characteristics of the patients and their anesthesia management will be examined in an observational study.

Description

Inclusion Criteria: • age > 18 years old who underwent elective VT ablation between 2020 - 2022,

• primary anesthetic type listed as general anesthesia

Exclusion Criteria: • age < 18 years,

• missing follow-up data,
• patients who have previously undergone epicardial ablation

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
weight	kilograms	2 years
sex	male %	2 years
age	years	2 years
height	meters	2 years
Hypertension	yes or no	2 years
Diabetes mellitus	yes or no	2 years
Coronary artery disease	yes or no	2 years
Chronic obstructive pulmonary disease	yes or no	2 years
Chronic kidney disease	yes or no	2 years
Systolic pulmonary artery pressure	mmHg	2 years
PAAINESD (Acute hemodynamic decompensation risk assessment, ranging from 0 to 35 points, 35 point is the worst) score	score 0-35	2 years
ASA ( American Society of Anesthesiologists (ASA) physical status classification ranging from I to IV	score I-IV	2 years
Hemoglobin	g/dl	2 years
glomerular filtration rate (eGFR)	ml/dak/1,73m2	2 years
Total procedural time	minutes	2 years
Fluoroscopy time	minutes	2 years
Ablation time	minutes	2 years
Left ventricular ejection	%	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Transient ischemic attack after procedure	yes or no	2 years
Exitus during the follow-up	yes or no	2 years
cause of death	End-Stage heart failure, VT storm	2 years

Collaborators and Investigators

• Sponsor: Eskisehir Osmangazi University
• Investigators: Principal Investigator: ferda yaman, Assoc prof, University of Eskisehir Osmangazi

Study record dates

Study Major Dates

• Study Start (Actual): August 30, 2024
• Primary Completion (Actual): September 30, 2024
• Study Completion (Actual): October 30, 2024

Study Registration Dates

• First Submitted: July 8, 2024
• First Submitted That Met QC Criteria: August 2, 2024
• First Posted (Actual): August 6, 2024

Study Record Updates

• Last Update Posted (Actual): May 2, 2025
• Last Update Submitted That Met QC Criteria: May 1, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: anesthesia; catheter ablation; risk assessment; ventricular tachycardia; Electrophysiology; electro-anatomic mapping
• Additional Relevant MeSH Terms: Cardiac Conduction System Disease; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Tachycardia; Tachycardia, Ventricular
• Other Study ID Numbers: EskisehirU

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No